JOURNAL ARTICLE

Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba.

  • Published In: Journal of Oncology Pharmacy Practice, 2026, v. 32, n. 4. P. 659 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Quinlan, Kaitlin; Geirnaert, Marc; Kotb, Rami; Dao, Vi; Minuk, Leonard; Kasian, Jayne; Rimmer, Emily 3 of 3

Abstract

This article focuses on a retrospective study evaluating the real-world use of subcutaneous (SC) Daratumumab, an anti-CD38 monoclonal antibody for treating multiple myeloma, with emphasis on reducing infusion-related reactions (IRRs) and time toxicity. The study included 197 adult patients treated between March 2022 and March 2023, reporting no IRRs with SC Daratumumab, which contrasts with prior intravenous (IV) administration where IRRs were more common. Based on these findings, the facility eliminated the 3-hour post-injection observation period for SC Daratumumab, improving healthcare efficiency and patient convenience, especially benefiting those in rural areas. The study highlights the potential for SC Daratumumab to reduce treatment burden and supports ongoing efforts to optimize administration protocols in oncology care.

Additional Information

  • Source:Journal of Oncology Pharmacy Practice. 2026/06, Vol. 32, Issue 4, p659
  • Document Type:Article
  • Subject Area:Geography and Cartography
  • Publication Date:2026
  • ISSN:1078-1552
  • DOI:10.1177/10781552241306741
  • Accession Number:193752606
  • Copyright Statement:Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.